What Abalos Therapeutics does

Abalos Therapeutics GmbH is a privately held, clinical-stage biotechnology company headquartered in Düsseldorf, Germany, that is developing arenavirus-based immuno-oncology therapies for the treatment of solid tumors and metastases. Founded in 2019 by Professors Karl Lang (Chair of Immunology at University Duisburg-Essen) and Philipp Lang (Director of Molecular Medicine II at Heinrich Heine University Düsseldorf), the company translates academic research on antiviral immune responses into a novel class of systemically administered cancer immunotherapies designed to overcome the central limitations of current immuno-oncology approaches, namely immune evasion, suppressive tumor microenvironments, inadequate T-cell activation, and tumor heterogeneity.

The company's core technology is its proprietary AdaptInnate platform, which harnesses the unique properties of mammarenaviruses that preferentially infect and persist in cancer cells and antigen-presenting cells without lysing them, thereby triggering a concerted innate and adaptive immune response against primary tumors and distant metastases. The lead clinical candidate, ABX-001, is a systemically administrable, non-oncolytic immunotherapy that is differentiated from traditional oncolytic virotherapy by its non-lytic mechanism; ABX-001 entered Phase 1 clinical evaluation in October 2025 in patients with advanced solid tumors at a single site in Düsseldorf. The platform is intended to support a broader pipeline of both naturally optimized and payload-carrying therapeutics designed for specific cancer indications, including potential combinations with bispecific T-cell engagers as indicated by the company's preclinical data presentation at SITC 2025.

Abalos operates a pre-commercial business model with no product revenue; future revenue is anticipated through traditional pharmaceutical drug sales or licensing transactions following regulatory approval. The company is funded by a syndicate of European life science investors that led EUR 43 million in cumulative Series A financing between 2019 and 2021, supplemented by a EUR 1.2 million BMBF grant in 2024. Its primary stakeholders today are its venture investors (Boehringer Ingelheim Venture Fund, COPARION, Hx Bio Ventures, Seventure Partners, NRW.BANK, High-Tech Gründerfonds, Gründerfonds Ruhr, and Ventura), academic collaborators (the Universities of Duisburg-Essen and Düsseldorf), and clinical investigators; end customers will be oncology patients reached through standard pharmaceutical distribution channels post-approval.

Name

Abalos Therapeutics

Legal name

Abalos Therapeutics GmbH

Website

https://abalos-tx.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Abalos Therapeutics is a Düsseldorf-based clinical-stage biotechnology company developing arenavirus-based immuno-oncology therapies via its proprietary AdaptInnate platform, with lead candidate ABX-001 currently in Phase 1 clinical trials for patients with advanced solid tumors.

Ownership category

akta.pro rank

Product category

Immuno-oncology Therapeutics

NAICS

Computer Systems Design and Related Services (54151), Computer Systems Design Services (541512)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

akta.pro secondary industries

Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC), Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

Keywords

• Immuno-oncology therapeutics
• Arenavirus cancer immunotherapy
• Viral immuno-oncology platform
• Solid tumor treatment
• Clinical stage biotechnology

Headquarters

HQ city

Essen

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Drug Development: Pre-revenue biotech company developing novel immunotherapies for cancer treatment. The company is in early clinical stages with lead candidate ABX-001 in Phase 1 trials for solid tumors. Revenue generation is anticipated through future drug sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Abalos Therapeutics develops systemically administrable immuno-virotherapies that use proprietary arenavirus vectors to trigger precise innate and adaptive immune responses against solid tumors. Its lead candidate, ABX-001, is a non-oncolytic arenavirus-based therapy in Phase 1 clinical trials for patients with advanced solid tumors. The proprietary AdaptInnate platform underpins a pipeline of naturally optimized and payload-carrying therapeutics for specific cancer indications.

Product overview

Abalos Therapeutics is developing a novel class of systemically administrable immuno-oncology candidates that trigger precise innate and adaptive immune responses from within a patient's tumor. The company's lead product is ABX-001, the first candidate from its proprietary AdaptInnate platform, currently in Phase 1 clinical trials for advanced solid tumors. The pipeline includes both naturally optimized as well as payload-carrying therapeutics designed for specific cancer indications. The AdaptInnate platform leverages arenavirus technology to stimulate comprehensive immune responses against primary tumors and distant metastases.

Differentiator

Problem solved

Functional benefit

Products and services

• ABX-001 Lead product candidate based on the AdaptInnate approach. A systemically administrable, non-oncolytic arenavirus-based immunotherapy designed to persist and replicate in cancerous and antigen-presenting cells without destroying them, triggering targeted, effective, and durable anti-tumor activity involving both innate and adaptive immune systems. Currently in Phase 1 clinical trials for advanced solid tumors.
• AdaptInnate Platform Proprietary technology platform harnessing the immunostimulatory and anti-tumoral properties of arenaviruses to trigger precise and directed immune responses against primary tumors and their metastases. Generates drug candidates that achieve persistent and far-reaching inflammation within the tumor, engaging all key immune organs in a concerted attack.

Quantifiable outcome

• Marked tumor regression in multiple preclinical tumor models
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Partnerships

Three partnerships are on record, tiered core and supporting.

• University of Duisburg-EssencoreStrategic or Co-development PartnerKey academic partner where company co-founder Prof. Dr. Karl Lang serves as Chair of Immunology. One of the largest and youngest universities in Germany with top research rankings.
• University of Düsseldorf (Heinrich Heine University)coreStrategic or Co-development PartnerAcademic partner where company co-founder Prof. Dr. Philipp Lang serves as Director of Department of Molecular Medicine II. Founded in 1965 with approximately 35,000 students.
• High-Tech Corporate ServicessupportingImplementation/ SI/ Consulting PartnerOperative services company specializing in establishment, structuring and management of administrative and financial divisions for startups, having supported over 100 startups.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Rigontec (acquired by MSD/Merck): Developed RIG-I RNA agonist immunotherapies for cancer; acquired by MSD in 2017. Abalos's CSO Jörg Vollmer was previously CSO at Rigontec, making it a directly comparable prior-stage precedent for Abalos's viral-immunotherapy approach and exit pathway.
• ViraTherapeutics (acquired by Boehringer Ingelheim): Developed the oncolytic VSV-GP virus platform; acquired by Boehringer Ingelheim. Abalos's CTO Dethardt Müller previously led CMC at ViraTherapeutics, making it the most direct operational precedent for Abalos's virus-based immuno-oncology strategy.
• Turnstone Biologics: Clinical-stage biotech developing viral immunotherapies and tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. Comparable in viral immunotherapy modality and solid tumor focus, with overlapping investor profiles.

Direct peers

• Targovax: Clinical-stage biotech developing oncolytic viruses and immune activators for solid tumors. Directly comparable in modality (virus-based cancer immunotherapy) and stage, though Targovax focuses on oncolytic rather than non-oncolytic mechanisms.
• Replimune: Clinical-stage company developing oncolytic immunotherapies for solid tumors. Comparable in virus-based cancer immunotherapy modality and in targeting of solid tumor indications, though using oncolytic rather than non-oncolytic mechanisms.
• PsiOxus Therapeutics: Develops enadenotucirev and other oncolytic virus immunotherapies for solid tumors. Directly comparable in virus-based cancer immunotherapy modality and in targeting of solid tumor indications.
• Vyriad: Clinical-stage developer of oncolytic virus therapies including measles and vesicular stomatitis virus constructs. Comparable in virus-based cancer immunotherapy modality and oncology focus.
• Cold Genesys: Clinical-stage immuno-oncology company developing oncolytic virus therapies (CG0070) for solid tumors including bladder cancer. Comparable in virus-based cancer immunotherapy modality.
• SillaJen: Developed Pexa-Vec, a GM-CSF-expressing oncolytic vaccinia virus for solid tumors. Comparable in virus-based cancer immunotherapy modality and oncology indication focus.
• Istari Oncology: Clinical-stage company developing PVSRIPO, a poliovirus-based immunotherapy for solid tumors. Comparable in virus-based cancer immunotherapy modality targeting solid tumors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/abalos-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abalos Therapeutics